BRAF and melanoma: Furthermore, dabrafenib (GSK2118436), another selective BRAF inhibitor[14] shows good clinical response rates not only for patients with p.V600E or p.V600K mutations but also in patients carrying a p.V600R, p.V600M or a double p.[V600E(;)V600M] mutation[15,16] giving new therapy options for melanoma patients with rare BRAF mutations.